Akèy › Kansè (tout kalite) › Ohio › Cincinnati
Etid klinik pou Kansè (tout kalite) nan Cincinnati, OH
27 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Cincinnati (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Ap rekriteFaz 2
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Ap rekriteFaz 3
- Oncology Hematology Care Clinical Trials, LLC, Fairfield · 15 mi lwen
Registry Study for Radiation Therapy Outcomes
Ap rekriteEtid obsèvasyon
- University of Cincinnati Medical Center, Cincinnati
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Ap rekriteFaz 3
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 mi lwen
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
Ap rekrite
- Cincinnati Children's Hospital Medical Center, Cincinnati
Pan Tumor Rollover Study
Ap rekriteFaz 2
- Oncology Hematology Care, Cincinnati
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- Oncology Hematology Care - Fairfield /ID# 280641, Fairfield · 15 mi lwen
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 mi lwen
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- Oncology Hematology Care, Inc., Cincinnati
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Edgewood · 8 mi lwen
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- USO - Oncology Hematology Care, Cincinnati
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- University of Cincinnati, Cincinnati
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Cincinnati Children's Hospital Medical Center, Cincinnati
International Rare Brain Tumor Registry
Ap rekriteEtid obsèvasyon
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- ak 1 plis
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Ap rekriteFaz 3
- University of Cincinnati Physicians Group, LLC, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Ap rekriteFaz 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
Ap rekriteEtid obsèvasyon
- TriHealth Cancer Institute, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- University of Cincinnati, Cincinnati
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
Ap rekriteFaz 2
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- TriHealth Cancer Institute, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Cincinnati
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Ap rekriteFaz 1
- The Christ Hospital Cancer Center, Cincinnati
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Ap rekriteEtid obsèvasyon
- University of Cincinnati Medical Center, Cincinnati
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Ap rekriteEtid obsèvasyon
- TriHealth Cancer Institute, Cincinnati
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Ap rekrite
- University of Cincinnati, Cincinnati
- West Chester Hospital (OH394), West Chester · 15 mi lwen
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY110 etid
- Boston, MA86 etid
- Los Angeles, CA73 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Durham, NC58 etid
- Washington, DC58 etid
- Chicago, IL51 etid
- Seattle, WA49 etid
- Atlanta, GA49 etid
- Arlington, VA48 etid
Lòt etid nan Cincinnati
- Kansè Poumon ki pa ti selil35 etid
- Kansè nan tete25 etid
- Ensifizyans kadyak24 etid
- Kansè kolorektal21 etid
- Leksemi mieloïd egi20 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Kansè poumon19 etid
- Obèsite19 etid
- Kansè pwostat18 etid
- Myelom Miltip17 etid
- Melanom17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.